SCHEMBL6183141

SCHEMBL6183141

CC(C)CCN(C(=O)OCc1ccccc1)C(=O)N(C)C(N)=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.43
ALDH1A1 P00352 3/20 0.41
ABCB1 P08183 1/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
KMT2A Q03164 1/20 0.38
CCR6 P51684 1/20 0.38
PAX8 Q06710 1/20 0.38
KCNA5 P22460 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183143 0.80 KCNA5 (0.41) ALOX5ALDH1A1CTSSCCR6PAX8
SCHEMBL22283338 0.79 ALDH1A1 (0.55) ALDH1A1ABCB1MAPTHPGDKMT2A
SCHEMBL6183149 0.79 CTSS (0.44) ALDH1A1CTSLCTSBCTSSCTSK
SCHEMBL7046274 0.78 XDH (0.41)
SCHEMBL6183588 0.77 CTSS (0.43) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL6183195 0.77 CTSS (0.42) ALDH1A1CTSLCTSBCTSSCTSK
SCHEMBL7799705 0.76 CCR6 (0.38) ALDH1A1ABCB1MAPTHPGDCHRNB2
SCHEMBL7790158 0.75 CCR6 (0.42) CTSLCTSBCCR6PAX8
SCHEMBL6181802 0.75 CTSS (0.53) CTSLCTSBCTSSCTSK
SCHEMBL6181959 0.75 CTSL (0.40) CTSLCTSBCTSSCTSKCCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed
EP-1161415-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-12 EP disclosed
WO-2000055126-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 ALOX5 1031/4885ALDH1A1 4049/4885ABCB1 966/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 ALOX5 1031/4885ALDH1A1 4049/4885ABCB1 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.